CTI BioPharma (CTIC) Reaches New 52-Week Low at $1.82

Share on StockTwits

CTI BioPharma Corp (NASDAQ:CTIC) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as $1.82 and last traded at $1.85, with a volume of 8999 shares. The stock had previously closed at $1.89.

A number of brokerages have recently issued reports on CTIC. ValuEngine upgraded shares of CTI BioPharma from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. BidaskClub lowered shares of CTI BioPharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 14th. Zacks Investment Research lowered shares of CTI BioPharma from a “hold” rating to a “sell” rating in a research note on Thursday, July 12th. JMP Securities set a $8.00 price target on shares of CTI BioPharma and gave the stock a “buy” rating in a research note on Tuesday, July 10th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $4.00 price target on shares of CTI BioPharma in a research note on Friday, July 20th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. CTI BioPharma presently has an average rating of “Buy” and an average price target of $5.83.

The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $113.08 million, a PE ratio of -1.48 and a beta of -0.32.

CTI BioPharma (NASDAQ:CTIC) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. CTI BioPharma had a negative net margin of 313.77% and a negative return on equity of 90.92%. The business had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.30 million. research analysts expect that CTI BioPharma Corp will post -0.6 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of CTIC. MetLife Investment Advisors LLC acquired a new position in CTI BioPharma during the second quarter worth about $137,000. Spark Investment Management LLC grew its position in CTI BioPharma by 241.9% during the first quarter. Spark Investment Management LLC now owns 40,000 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 28,300 shares during the period. Barclays PLC grew its position in CTI BioPharma by 9,349.0% during the first quarter. Barclays PLC now owns 49,324 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 48,802 shares during the period. Element Capital Management LLC acquired a new position in CTI BioPharma during the first quarter worth about $205,000. Finally, Rhumbline Advisers acquired a new position in CTI BioPharma during the second quarter worth about $243,000. Institutional investors own 63.58% of the company’s stock.

CTI BioPharma Company Profile (NASDAQ:CTIC)

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Recommended Story: How Do You Make Money With Penny Stocks?

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply